GSK, Eon settle Wellbutrin SR dispute
Executive Summary
GlaxoSmithKline and Eon reach settlement in Wellbutrin SR patent lawsuit. Agreement was reached before a Manhattan federal judge ruled on GSK's infringement claims. An appeals court ruled in a separate case that Impax' generic bupropion sustained-release does not infringe GSK's patent. The Eon case involved similar issues, and the settlement is effective if the Impax ruling is not reversed on appeal. Eon launched its generic "at risk" Jan. 15; Watson and Impax/Teva subsequently entered the market (1"The Pink Sheet" March 29, 2004, p. 27)...
You may also be interested in...
Wellbutrin SR Generics Multiply As Andrx Relinquishes Exclusivity
Andrx' agreement to give up its first-to-file ANDA exclusivity on a generic of GlaxoSmithKline's Wellbutrin SR 150 mg tablet means six companies will immediately share in the profits on sales of the generic antidepressant
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.